A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
ConditionCystic Fibrosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorNicole Hamblett
About this trial
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators.
Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.
Eligibility criteria
Qualifiers
Sweat chloride ≥ 60 mEq/liter by quantitative pilocarpine iontophoresis test (QPIT)
Two well-characterized disease-causing pathogenic variants in the CFTR gene
One well-characterized disease-causing mutation and a second CFTR variant (with variable or uncharacterized disease-causing potential) and sweat ≥ 30 mmol/liter with permission of the study sponsor-investigators
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Nicole Hamblett
Lead sponsor
Seattle Children's Hospital
Sponsor institution
Washington University School of Medicine
Collaborator
Florida State University
Collaborator
University of North Carolina, Chapel Hill
Collaborator
University of Toronto
Collaborator
Cystic Fibrosis Foundation
Collaborator
Source ClinicalTrials.gov